594 related articles for article (PubMed ID: 30403573)
1. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.
Frick M; Chan W; Arends CM; Hablesreiter R; Halik A; Heuser M; Michonneau D; Blau O; Hoyer K; Christen F; Galan-Sousa J; Noerenberg D; Wais V; Stadler M; Yoshida K; Schetelig J; Schuler E; Thol F; Clappier E; Christopeit M; Ayuk F; Bornhäuser M; Blau IW; Ogawa S; Zemojtel T; Gerbitz A; Wagner EM; Spriewald BM; Schrezenmeier H; Kuchenbauer F; Kobbe G; Wiesneth M; Koldehoff M; Socié G; Kroeger N; Bullinger L; Thiede C; Damm F
J Clin Oncol; 2019 Feb; 37(5):375-385. PubMed ID: 30403573
[TBL] [Abstract][Full Text] [Related]
2. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
Gibson CJ; Kim HT; Zhao L; Murdock HM; Hambley B; Ogata A; Madero-Marroquin R; Wang S; Green L; Fleharty M; Dougan T; Cheng CA; Blumenstiel B; Cibulskis C; Tsuji J; Duran M; Gocke CD; Antin JH; Nikiforow S; DeZern AE; Chen YB; Ho VT; Jones RJ; Lennon NJ; Walt DR; Ritz J; Soiffer RJ; Gondek LP; Lindsley RC
J Clin Oncol; 2022 Jan; 40(2):189-201. PubMed ID: 34793200
[TBL] [Abstract][Full Text] [Related]
3. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
5. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry.
Gillis N; Padron E; Wang T; Chen K; DeVos JD; Spellman SR; Lee SJ; Kitko CL; MacMillan ML; West J; Tang YH; Teng M; McNulty S; Druley TE; Pidala JA; Lazaryan A
Transplant Cell Ther; 2023 Oct; 29(10):640.e1-640.e8. PubMed ID: 37517612
[TBL] [Abstract][Full Text] [Related]
6. Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse.
Newell LF; Williams T; Liu J; Yu Y; Chen Y; Booth GC; Knight RJ; Goslee KR; Cook RJ; Leonard J; Meyers G; Traer E; Press RD; Fan G; Wang Y; Raess PW; Maziarz RT; Dunlap J
Transplant Cell Ther; 2021 Aug; 27(8):662.e1-662.e9. PubMed ID: 33901720
[TBL] [Abstract][Full Text] [Related]
7. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
Styczynski J; Tridello G; Gil L; Ljungman P; Hoek J; Iacobelli S; Ward KN; Cordonnier C; Einsele H; Socie G; Milpied N; Veelken H; Chevallier P; Yakoub-Agha I; Maertens J; Blaise D; Cornelissen J; Michallet M; Daguindau E; Petersen E; Passweg J; Greinix H; Duarte RF; Kröger N; Dreger P; Mohty M; Nagler A; Cesaro S
J Clin Oncol; 2016 Jul; 34(19):2212-20. PubMed ID: 27091716
[TBL] [Abstract][Full Text] [Related]
8. Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up.
Kim KH; Kim T; Novitzky-Basso I; Lee H; Yoo Y; Ahn JS; Pasic I; Law A; Lam W; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Zhang Z; Kaushansky N; Brilon Y; Chapal-Ilani N; Biezuner T; Shlush LI; Kim DDH
Haematologica; 2023 Jul; 108(7):1817-1826. PubMed ID: 36727396
[TBL] [Abstract][Full Text] [Related]
9. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
[TBL] [Abstract][Full Text] [Related]
14. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
Mehta J; Gordon LI; Tallman MS; Winter JN; Evens AM; Frankfurt O; Williams SF; Grinblatt D; Kaminer L; Meagher R; Singhal S
Bone Marrow Transplant; 2006 Jul; 38(2):95-100. PubMed ID: 16751789
[TBL] [Abstract][Full Text] [Related]
15. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
16. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
17. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors.
Kang JM; Kim YJ; Kim JY; Cho EJ; Lee JH; Lee MH; Lee SH; Sung KW; Koo HH; Yoo KH
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1091-8. PubMed ID: 25708217
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies].
Yu S; Dai M; Sun J; Fan Z; Huang F; Zhang Y; Jiang Q; Zhou H; Xu D; Meng F; Liu Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):826-30. PubMed ID: 25246252
[TBL] [Abstract][Full Text] [Related]
19. Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.
Rockstroh A; Al-Ali HK; Lange T; Pönisch W; Krahl R; Cross M; Behre G; Niederwieser D; Pfrepper C
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2193-203. PubMed ID: 26129640
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
Brunner AM; Kim HT; Coughlin E; Alyea EP; Armand P; Ballen KK; Cutler C; Dey BR; Glotzbecker B; Koreth J; McAfee SL; Spitzer TR; Soiffer RJ; Antin JH; Ho VT; Chen YB
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1374-80. PubMed ID: 23791626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
